Rapport Therapeutics, Inc. (RAPP): Cash & Equivalents
$52.65M
As of 2025-12-31
$63.61M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.65M | -7.3% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $56.80M | -19.0% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $70.17M | n/a | 2025-03-11, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $52.65M | -7.3% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $40.58M | -28.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $48.30M | -65.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $46.94M | -23.8% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
Compare RAPP, RIGL, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗